Legal status · United States
Is Anti-IL-11 legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Anti-IL-11 is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, no human study is cited on its profile.
Anti-IL-11 in the United States at a glance
| Classification | Investigational, not approved |
|---|---|
| Note | No anti-IL-11 agent is approved. Early human development targets fibrotic disease rather than ageing. Note that recombinant IL-11 was itself once an approved drug, for the opposite purpose. |
| FDA approval status | No anti-IL-11 agent is approved for any indication. Recombinant IL-11 itself, oprelvekin, was previously an approved drug for thrombocytopenia, which is the opposite intervention. |
| Human studies cited | 0 of 1 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Anti-IL-11 profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
Anti-IL-11 is being studied in registered clinical trials but has not received FDA marketing approval in the United States.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What Anti-IL-11 is
Blocking a single inflammatory cytokine extended healthspan and lifespan in mice, and it worked when started in already old animals. No human ageing trial exists.
This is one of the more striking mouse results in recent ageing biology, and the detail that matters is when treatment started. Interleukin-11 is a cytokine in the interleukin-6 family that rises with age and drives fibrosis and inflammatory signalling.
Mechanism: Interleukin-11 signals through a receptor complex using IL-11RA and the shared gp130 subunit, activating JAK and STAT3 and also ERK signalling. It is a driver of fibroblast activation and fibrosis across organs, and its expression rises with age.
Regulatory history: No anti-IL-11 agent is approved for any indication. Recombinant IL-11 itself, oprelvekin, was previously an approved drug for thrombocytopenia, which is the opposite intervention.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Anti-IL-11 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Anti-IL-11 in other countries
Frequently asked questions
Is Anti-IL-11 legal in the United States?
No. Anti-IL-11 is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, no human study is cited on its profile. Note: No anti-IL-11 agent is approved. Early human development targets fibrotic disease rather than ageing. Note that recombinant IL-11 was itself once an approved drug, for the opposite purpose.
Can I buy Anti-IL-11 in the United States?
No approved product exists to buy. In the United States Anti-IL-11 is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: No anti-IL-11 agent is approved. Early human development targets fibrotic disease rather than ageing. Note that recombinant IL-11 was itself once an approved drug, for the opposite purpose.
Is Anti-IL-11 FDA approved?
No. FDA status: No anti-IL-11 agent is approved for any indication. Recombinant IL-11 itself, oprelvekin, was previously an approved drug for thrombocytopenia, which is the opposite intervention.. Current US classification: "Investigational, not approved". On the evidence, no human study is cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Anti-IL-11 live on its compound profile.
Anti-IL-11 profileThis page is general information about the regulatory status of Anti-IL-11 in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.